Prevention

More than 13 million children did not receive their first DTP vaccine dose in 2019—and investigators anticipate the 2020 rate will be worse.

Data show none of the treated volunteers to develop COVID-19 experienced a severe form of the disease, versus 11 given placebo.

The Vanderbilt Professor of Preventive Medicine shares thoughts on the first potential COVID-19 vaccine, at a time of record new daily cases.

The biotechnology has reached it COVID-19 case accrual mark, and announced plans to submit data to an independent review board.

The company is still awaiting its threshold for total COVID-19 infections in its 44,000-patient assessment. Nonetheless, they believe they have made history.

We asked a simple question to our IDWeek experts: has COVID-19 taken attention away from any greater infectious disease issues?

Vaccination for VZV and HPV requires special consideration in immunocompromised patients. They are at risk for more severe viral illnesses if not immune, but they may also have decreased response to, and increased adverse effects from, vaccines.

A glimpse into FDA advisor perspective just weeks before EUAs are anticipated to be sent.

The presenting IDWeek author discusses the implication of promising phase 3 data for a new HBV vaccine.

New data suggest collaboration between hospital prescribers and stewardship teams is still not perfected.

New data show the pandemic, and a lack of efficacious therapies, did harm to 4 years' worth of stewardship.

The conclusion to the independent safety review punctuates a 50-day period of scrutiny and discussion around 2 non-fatal adverse events reported in patients.

New head-to-head phase 3 data show a promising potential new HBV vaccine may join the market in the near future.

A vaccine developer joins for a firsthand discussion on the development, research, and distribution process.

Pfizer anticipates to have completed FDA-mandated safety data a month from now. An EUA application should shortly follow.

The Meharry and Vanderbilt-based expert shares insights into reaching less trustful populations on the first podcast episode.

In consideration of the idea that the pandemic may lead to greater knowledge and adoption of preventive health measures.

Numerous candidates are in late-stage assessment. An expert shares what the diverse agents should show before being considered for regulation.

The new guidance bucks against the White House's campaign message of an available prophylaxis by the election.

Perspective on the ongoing independent safety reviews for one of the more promising vaccine candidates.

Incredible resources and effort have been put into the COVID-19 response, but other infectious disease priorities have also been displaced. Patrick Howie, CEO of a firm which aggregates clinical analysis and data, explains.

A new study in The Lancet maps trends in vaccine confidence around the world.

New guidance from the Infectious Diseases Society of America offers timely practice advice for the clinical treatment of three of the most common drug-resistant pathogens.